Document is current
Any future updates will be listed below
-
Authors
Wilson, Rebecca J. https://orcid.org/0009-0000-8203-923X
Ramlogan-Steel, Charmaine A. https://orcid.org/0000-0002-6810-4602
Deasy, William J. https://orcid.org/0000-0003-1864-9759
Greenstein, Sarah J. https://orcid.org/0009-0006-0723-4530
Layton, Christopher J. https://orcid.org/0000-0001-6933-9991
Steel, Jason C. https://orcid.org/0000-0003-3608-7542
-
Funding
Funding for this research was provided by:
Central Queensland University
- License Information
-
More Information
Article History
Accepted: 3 June 2026
First Online: 25 June 2026
Declarations
Conflicts of interest/Competing interests: Christopher J. Layton is the founder of Ocugene, a preclinical, pre-revenue gene therapy company developing AAV-based therapies for ocular disease. Jason C. Steel has served as a consultant for Ocugene. Christopher J. Layton and Jason C. Steel are inventors on issued and pending patents in Australia and the USA relating to AAV and adenoviral vector technologies. Rebecca J. Wilson, Charmaine A. Ramlogan-Steel, William J. Deasy and Sarah J. Greenstein have no conflicts of interest that are directly relevant to the content of this article.
Ethical Approval: Not applicable.
Consent to Participate: Not applicable.
Consent for Publication: Not applicable.
Code Availability: Not applicable.
Availability of Data and Material: No datasets were generated or analysed during the current study.
Authors’ Contributions: Conceptualisation: RJW, JCS; writing, review and editing: RJW, JCS, CAR-S, WJD, CJL, SJG; visualisation: RJW, JCS, SJG; project administration: JCS, CAR-S. All authors have read and agreed to the published version of the manuscript. All content, scientific ideas and conclusions remain the sole responsibility of the authors, who have thoroughly reviewed and edited the entire manuscript. Figures were created with BioRender ( ) [Accessed 19 Jan 2026].
